Tablet Tooling Coating Reduces Formulation Sticking

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-12-02-2013
Volume 37
Issue 12

Tablet Tooling Coating Reduces Formulation Sticking

PharmaCote CX and CX+,  an enhanced Chromium Nitride, are a range of coatings developed to improve the performance of substrate material for punches and dies. The coating offers a smooth finish and anti-stick performance, the company reports. PharmaCote CX provides prolonged tooling life due to a multi-layered application. It also offers up to 13 times more corrosion resistance than PharmaCote HC (Hard Chromium) and up to two times the life of PharmaCote CN (Chromium Nitride).

I Holland

Articles in this issue
Rail-Mounted Fluid Bed Dryers Allow Cleaning Access
Biotechnology Innovation and Growth in Israel
Biotechnology Innovation and Growth in Israel
NEW_SiegfriedSchmitt_New-830192-1408530638094.jpg
Drug Manufacturing Focus: Why India?
Milmo_Sean-830460-1408530369145.jpg
Regulation of Biosimilars: A Matter of Variability, Similarity, and Comparability
Clinical Trials Head East to Asia
Clinical Trials Head East to Asia
Miller_Jim-830183-1408530640566.jpg
Climate Change in Outsourcing
Deficiencies Found in API Inspections
Q&A with Brian Galliher, Cook Pharmica
Q&A with Brian Galliher, Cook Pharmica
Smith_Tim-830428-1408530412176.jpg
Inspiring the Next Generation
Establishing a Minimum Incubation Time for Biological Indicators
Establishing a Minimum Incubation Time for Biological Indicators
Implementing QbD in Sterile Manufacturing
Implementing QbD in Sterile Manufacturing
Wechsler_Jill-830087-1408530742383.jpg
Opioid Regulation Challenges FDA and Manufacturers
NEW_Schenck-830505-1408530288927.jpg
Low Feed Rate Feeder Designed for Pharmaceutical Processes
NEW_IHolland-830502-1408530294595.jpg
Tablet Tooling Coating Reduces Formulation Sticking
Industry Optimism Outweighs Personal Job Security
Industry Optimism Outweighs Personal Job Security
Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

ACG to Showcase Sustainability Innovations at Pharmapack Europe 2025

Susan Haigney
January 21st 2025
Article

The company will be featuring its sustainable packaging solutions at the event in Paris on Jan. 22–23, 2025.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Samsung Biologics Scores Major Manufacturing Deal Worth Over $1.4 Billion with European Pharma Company

Feliza Mirasol
January 17th 2025
Article

Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

PackGene and GC4K Team Up Along with Weill Cornell Medicine for Gene Therapy to Treat Rare Neurological Disease

Feliza Mirasol
January 11th 2025
Article

Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia type 56, a particularly rare neurological disease.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

With New Funding, Orbis Medicines to Develop Oral Macrocycles as Alternative to Biologic Drugs

Feliza Mirasol
January 7th 2025
Article

With the new $94 million (€90 million) funding, the company will develop its pipeline of oral macrocycle drugs, nCycles, against validated biologic targets.